CWIG
VOR icon

Chung Wu Investment Group’s Vor Biopharma VOR Stock Holding History

Chung Wu Investment Group’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,300
Closed -$109K – 296
2025
Q4 		$109K Buy
+8,300
New +$155K 0.09% 106

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Chung Wu Investment Group's VOR Position: Q1 2026 in Review

Chung Wu Investment Group sold out of Vor Biopharma (VOR) in Q1 2026, closing a stake of 8,300 shares — an estimated $109K sold.

Chung Wu Investment Group first reported a position in VOR in Q4 2025 and held it in 1 quarter. The position peaked at $109K in Q4 2025. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Chung Wu Investment Group reported no remaining Vor Biopharma position as of Q1 2026 after selling out during the quarter.
  • Chung Wu Investment Group sold 8,300 Vor Biopharma shares in Q1 2026, an estimated $109K.
  • Chung Wu Investment Group first reported a position in Vor Biopharma in Q4 2025 and held it in 1 quarter.
  • Chung Wu Investment Group's Vor Biopharma position peaked at $109K in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Chung Wu Investment Group's 13F filing for Q1 2026, filed 12 May 2026.